ACADIA Pharmaceuticals Inc. (ACAD): Today's Featured Drugs Laggard
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
(
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.2%. By the end of trading, ACADIA Pharmaceuticals fell $0.41 (-2.1%) to $18.63 on light volume. Throughout the day, 1,124,880 shares of ACADIA Pharmaceuticals exchanged hands as compared to its average daily volume of 3,426,700 shares. The stock ranged in price between $18.50-$19.06 after having opened the day at $18.94 as compared to the previous trading day's close of $19.04. Other companies within the Drugs industry that declined today were:
(
), down 37.2%,
IntelliPharmaCeutics International
(
), down 20.4%,
(
), down 16.9% and
(
), down 16.1%.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. ACADIA Pharmaceuticals has a market cap of $1.7 billion and is part of the health care sector. Shares are up 309.5% year to date as of the close of trading on Thursday. Currently there are 8 analysts that rate ACADIA Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.
TheStreet Ratings rates
ACADIA Pharmaceuticals
as a
. Among the areas we feel are negative, one of the most important has been weak operating cash flow.
- You can view the full ACADIA Pharmaceuticals Ratings Report.
On the positive front,
Senesco Technologies
(
SNTI
), up 56.1%,
(
), up 49.7%,
(
), up 24.7% and
(
), up 16.3% , were all gainers within the drugs industry with
(
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
- Find other investment ideas from our top rated ETFs lists.
null